好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Infertility in Women with Migraine: The Impact of Fertility Treatment and Stress
Headache
P8 - Poster Session 8 (11:45 AM-12:45 PM)
15-004
N/A
Migraine is a common and disabling neurological condition that disproportionately affects women, particularly during their reproductive years. Infertility is also very common, and women have more access to reproductive treatments such as in vitro fertilization (IVF) now than ever before. Despite known associations between migraine, gynecological disorders, and psychological distress, little research has examined how migraine intersects with infertility and related treatments. This study aims to explore the relationship between migraine and infertility, including treatment effects and emotional impact.
This cross-sectional study used a ten-question online survey to explore infertility experiences among adult women with migraine from February to April 2025. Participants were recruited via social media posts shared by Miles for Migraine and relevant Facebook groups, with eligibility limited to women aged 18 and older.
In our survey population of women with migraine, 46/81 (56.8%) reported difficulties with infertility, with common causes including unexplained infertility, PCOS, male factor infertility, anovulation and poor egg reserve. Of the women, 42/46 (91.3%) reported having tried fertility treatments including timed intercourse with hormonal therapy, intrauterine insemination, and in vitro fertilization. Of those who received fertility treatment, most reported worsening of migraine (15/42, 35.7%), and most who became pregnant reported improvement in migraine (11/42, 26.2%). Respondents in our study population had high rates of stress related to infertility with a median of 4 on a 1-5 scale (IQR=2). 
Participants in our survey had high rates of infertility and infertility related stress. Likewise, the factors contributing to infertility that have been previously associated with migraine were present in our population. Participants generally noted worsening in migraine with fertility treatment suggesting a possible association between hormonal therapy and migraine. Results from this study suggest a need for stress management as an early intervention for women with migraine who are undergoing fertility treatment. 
Authors/Disclosures
Liza Smirnoff, MD (University of Miami Health)
PRESENTER 		The institution of Dr. Smirnoff has received research support from NIH NeuroNext.
Jasmin Jean, MD (Mount Sinai Hospital) Dr. Jean has nothing to disclose.
Teshamae Monteith, MD, FAAN (University of Miami) Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for American Headache Society . Dr. Monteith has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Monteith has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merz. Dr. Monteith has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva . Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN . Dr. Monteith has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. Dr. Monteith has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN . Dr. Monteith has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Cephalalgia. Dr. Monteith has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for New England Journal of Medicine JW. The institution of Dr. Monteith has received research support from AbbVie. The institution of Dr. Monteith has received research support from lilly. The institution of Dr. Monteith has received research support from Ipsen. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a 好色先生 with Medscape. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a 好色先生 with Massachusetts Medical Society . Dr. Monteith has a non-compensated relationship as a President Elect with Florida Society of Neurology that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a Editorial Board /Board Member with American Migraine Foundation that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a Board Member with International Headache Society that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a author with Pfizer that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a author with Abbvie that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a author with Theranica that is relevant to AAN interests or activities.